Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

December 5, 2017 by Tom Ulrich
Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma
Credit : Susanna M. Hamilton, Broad Communications

Pediatric cancers tend to have relatively "quiet" genomes compared to tumors in adults. They harbor fewer discrete genetic mutations, especially in genes for readily "druggable" targets (such as protein kinases). Instead, these tumors tend to feature other kinds of genetic alterations, such as duplications or translocations.

Such is often the case in high-risk forms of , a rare childhood tumor of the nerves. The gene MYCN is frequently amplified (duplicated many times) in these cancers, forcing the tumor cells to overproduce a transcription factor—a kind of protein that helps turn genes on and off and is very difficult to target directly.

In a paper in the Journal of Clinical Investigation, a team led by postdoctoral researcher Liying Chen and Broad institute member and Dana-Farber Cancer Institute pediatric hematologic malignancies co-director Kimberly Stegmaier (both with the Broad Cancer Program) announced the discovery of a potentially druggable weakness in MCYN-amplified neuroblastomas: a survival dependency on EZH2, a MYCN target gene that helps manage many aspects of a cell's identity and behavior.

The starting point for the team's study was the Cancer Dependency Map, a joint effort bringing together researchers from the Cancer Program's Project Achilles and Cancer Data Science teams, the institute's Genetic Perturbation Platform, and other Broad groups. Chen, Stegmaier, and their colleagues used the Dependency Map team's genome-scale CRISPR screening data to discover their initial list of neuroblastoma targets, a list in which EZH2 and two of its biochemical partners, EED and SUZ12, featured prominently.

Through a combination of informatic, genetic, and pharmacological experiments using cell lines and animal models, the team found that:

  1. The MYCN protein directly governs EZH2 expression.
  2. The EZH2 protein, in turn, blocks suppressor activity in cells and prevents them from growing into mature neurons ( tend to look and act like "immature" nerve ).
  3. Silencing EZH2 using RNA interference or inhibiting it with drug compounds impaired neuroblastoma growth in vitro and in vivo.

Taken together, the team's findings suggest that EZH2 could be a potent and attractive target for developing sorely needed new treatment options against high-risk neuroblastoma.

Explore further: Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors

More information: Liying Chen et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI90793

Related Stories

Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors

February 21, 2013
Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors ...

Researchers identify genes fueling neuroblastoma spread

August 31, 2017
For the first time, Mayo Clinic researchers and colleagues present data on how nervous system tumors, called neuroblastomas, spread. Their paper, published in Cancer Cell, clarifies the relationship between two genes that ...

Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs

April 9, 2013
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, ...

New research points to potential for more targeted treatments of neuroblastoma tumors

June 19, 2017
Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted ...

Editing false positives from cancer dependency maps drawn with CRISPR

October 31, 2017
The Broad Cancer Dependency Map team adds CRISPR-based data from 342 cancer cell lines to their growing catalog of genetic dependencies in cancer, and a new method for ensuring that data's accuracy.

The paradoxical roles of well-known cancer genes are mediated by oxygen levels in breast cancer

January 4, 2017
Oxygen deprivation, or hypoxia, has been identified by A*STAR researchers as a key factor in switching the function of major cancer genes from tumor-promoting to tumor-suppressing in a breast cancer subtype, suggesting the ...

Recommended for you

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.